GlassScriptPhysician profile
Mirha Avdagic
NPI 1154625887
$2,461.52
in general payments reported to CMS, 2019-2025
21 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $276 · 2021: $155 · 2022: $152 · 2023: $72.04 · 2024: $355 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $538.55 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $293.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $242.03 | 2019-2024 | Shingrix, Arexvy |
| Pfizer INC. | $236.36 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $191.92 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $189.02 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $166.09 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $93.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $88.02 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.26 | 2019-2020 | |
| Allergan, INC. | $58.19 | 2019 | |
| Exact Sciences Corporation | $54.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $38.66 | 2019 | |
| Amarin Pharma, INC. | $25.12 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.36 | 2019 | |
| Nevro Corp. | $20.76 | 2022 | |
| Axsome Therapeutics, INC. | $19.97 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $16.27 | 2019 | |
| Merck Sharp & Dohme LLC | $16.22 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Circassia INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirha Avdagic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.